High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: A randomised, double-blind, phase 3, placebo-controlled trial

The Lancet Neurology

Volumn 12, Issue 11, 2013, Pages 1049-1058

  Ginsberg, Myron D ^a   Palesch, Yuko Y ^b   Hill, Michael D ^c   Martin, Renee H ^b   Moy, Claudia S ^d   Barsan, William G ^e   Waldman, Bonnie D ^b   Tamariz, Diego ^a   Ryckborst, Karla J ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885369695     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70223-0     Document Type: Article

References (53)

1. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:143-152.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
3. Norrving B, Kissela B The global burden of stroke and need for a continuum of care. Neurology 2013, 80:S5-12.
4. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke 2001, 32:1732-1738.
5. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013, 309:2480-2488.
6. Ginsberg MD Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008, 55:363-389.
7. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012, 7:407-418.
8. Cook DJ, Tymianski M Translating promising preclinical neuroprotective therapies to human stroke trials. Expert Rev Cardiovasc Ther 2011, 9:433-449.
9. Belayev L, Zhao W, Pattany PM, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 1998, 29:2587-2599.
10. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001, 32:553-560.
11. Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res 1998, 804:105-113.
12. Belayev L, Pinard E, Nallet H, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002, 33:1077-1084.
13. DeFazio RA, Zhao W, Deng X, Obenaus A, Ginsberg MD Albumin therapy enhances collateral perfusion after laser-induced middle cerebral artery branch occlusion: a laser speckle contrast flow study. J Cereb Blood Flow Metab 2012, 32:2012-2022.
14. Nimmagadda A, Park H-P, Prado R, Ginsberg MD Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study. Stroke 2008, 39:198-204.
15. Park HP, Nimmagadda A, DeFazio RA, Busto R, Prado R, Ginsberg MD Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study. Stroke 2008, 39:1556-1562.
16. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke. Physiological responses and safety results. Stroke 2006, 37:2100-2106.
17. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke. II. Neurological outcome and efficacy-analysis. Stroke 2006, 37:2107-2114.
18. Ginsberg MD, Palesch YY, Martin RH, et al. The albumin in Acute Stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke 2011, 42:119-127.
19. Pocock S Clinical Trials-a practical approach 1983, Wiley, New York.
20. Myburgh J, Cooper J, Finfer S, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007, 357:874-884.
21. Williams LS, Weinberger M, Harris LE, Clark DO, Biller J Development of a stroke-specific quality of life scale. Stroke 1999, 30:1362-1369.
22. O'Donnell WE, Reynolds DM, De Soto CB Neuropsychological impairment scale (NIS): initial validation study using trailmaking test (A & B) and WAIS digit symbol (scaled score) in a mixed grouping of psychiatric, neurological, and normal patients. J Clin Psychol 1983, 39:746-748.
23. EuroQol-a new facility for the measurement of health-related quality of life. Health Pol 1990, 16:199-208. The EuroQol Group.
24. Dolan P Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108.
25. Jones WJ, Williams LS, Meschia JF Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination. Stroke 2001, 32:2232-2236.
26. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. NINDS rt-PA Stroke Study Group.
27. Hill MD, Martin RH, Palesch YY, et al. The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis. Stroke 2011, 42:1621-1625.
28. O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
29. Lan KKG, DeMets DI Design and analysis of group sequential tests based on type-I error spending rate function. Biometrika 1987, 74:149-154.
30. Pampallona S, Tsiatis AA, Kim KM Interim monitoring of group sequential trials using spending functions for the Type I and Type II error probabilities. Drug Info J 2001, 35:1113-1121.
31. Fleiss JL, Tytun A, Ury HK A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 1980, 36:343-346.
32. Friedman LM, Furberg CD, DeMets DL Fundamentals of clinical trials 1998, Springer-Verlag, New York.
33. Adams HP, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008, 39:87-99.
34. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005, 36:880-890. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators.
35. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
36. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703.
37. Shobha N, Buchan AM, Hill MD Thrombolysis at 3-4·5 hours after acute ischemic stroke onset-02evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2011, 31:223-228.
38. Goslinga H, Eijzenbach V, Heuvelmans JH, et al. Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke. Stroke 1992, 23:181-188.
39. Koch S, Concha M, Wazzan T, Romano JG, Forteza A High dose human serum albumin for the treatment of acute ischemic stroke: a safety study. Neurocrit Care 2004, 1:335-341.
40. Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012, 380:349-357.
41. Rosenberg G, Bornstein N, Diener HC, Gorelick PB, Shuaib A, Lees K The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study. Int J Stroke 2011, 6:362-367.
42. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-e656.
43. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007, 357:562-571.
44. Sacco RL, DeRosa JT, Haley EC, et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 2001, 285:1719-1728.
45. Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000, 355:1949-1954.
46. Dirnagl U Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006, 26:1465-1478.
47. Dirnagl U, Becker K, Meisel A Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol 2009, 8:398-412.
48. Iadecola C, Anrather J Stroke research at a crossroad: asking the brain for directions. Nat Neurosci 2011, 14:1363-1368.
49. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW 1026 experimental treatments in acute stroke. Ann Neurol 2006, 59:467-477.
50. Yusuf S Challenges in the conduct and interpretation of phase II (pilot) randomized trials. Am Heart J 2000, 139:S136-S142.
51. Ammit AJ, O'Neill C Studies of the nature of the binding by albumin of platelet-activating factor released from cells. J Biol Chem 1997, 272:18772-18778.
52. Gresele P, Deckmyn H, Huybrechts E, Vermylen J Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol 1984, 33:2083-2088.
53. Jorgensen KA, Stoffersen E On the inhibitory effect of albumin on platelet aggregation. Thromb Res 1980, 17:13-18.